Group One Trading
KPTI icon

Group One Trading’s Karyopharm Therapeutics KPTI Stock Holding History

Group One Trading’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.81M Buy
324,900
+104,200
+47% +$794K ﹤0.01% 2168
2025
Q4 		$1.62M Buy
220,700
+120,300
+120% +$736K ﹤0.01% 2459
2025
Q3 		$657K Buy
100,400
+95,700
+2,036% +$515K ﹤0.01% 3428
2025
Q2 		$20.3K Sell
4,700
-2,400
-34% -$11.8K ﹤0.01% 6257
2025
Q1 		$26.6K Buy
7,100
+4,220
+147% +$36K ﹤0.01% 5628
2024
Q4 		$29.2K Sell
2,880
-44,033
-94% -$532K ﹤0.01% 5450
2024
Q3 		$584K Buy
46,913
+113
+0.2% +$1.4K ﹤0.01% 2742
2024
Q2 		$609K Buy
46,800
+45,420
+3,291% +$752K ﹤0.01% 2381
2024
Q1 		$31.3K Sell
1,380
-4,593
-77% -$80.5K ﹤0.01% 5084
2023
Q4 		$77.5K Sell
5,973
-1,974
-25% -$26.6K ﹤0.01% 4686
2023
Q3 		$160K Buy
7,947
+2,887
+57% +$64.8K ﹤0.01% 4005
2023
Q2 		$136K Buy
5,060
+4,693
+1,279% +$202K ﹤0.01% 4316
2023
Q1 		$21.4K Sell
367
-14,713
-98% -$726K ﹤0.01% 5456
2022
Q4 		$769K Sell
15,080
-1,720
-10% -$119K ﹤0.01% 2647
2022
Q3 		$1.38M Sell
16,800
-3,120
-16% -$233K ﹤0.01% 2244
2022
Q2 		$1.35M Buy
19,920
+327
+2% +$30K ﹤0.01% 2444
2022
Q1 		$2.17M Buy
19,593
+6,240
+47% +$778K ﹤0.01% 2323
2021
Q4 		$1.29M Buy
13,353
+7,626
+133% +$760K ﹤0.01% 3080
2021
Q3 		$500K Sell
5,727
-2,346
-29% -$244K ﹤0.01% 4185
2021
Q2 		$1.25M Sell
8,073
-507
-6% -$73.6K ﹤0.01% 3149
2021
Q1 		$1.35M Buy
8,580
+1,753
+26% +$369K ﹤0.01% 2884
2020
Q4 		$1.58M Sell
6,827
-3,273
-32% -$758K ﹤0.01% 2240
2020
Q3 		$2.21M Buy
10,100
+2,333
+30% +$571K 0.01% 1516
2020
Q2 		$2.21M Sell
7,767
-520
-6% -$154K 0.01% 1401
2020
Q1 		$2.39M Sell
8,287
-8,160
-50% -$2.25M 0.02% 930
2019
Q4 		$4.73M Buy
16,447
+15,487
+1,613% +$3.36M 0.03% 730
2019
Q3 		$139K Buy
960
+660
+220% +$89.5K ﹤0.01% 3347
2019
Q2 		$27K Sell
300
-747
-71% -$60K ﹤0.01% 4055
2019
Q1 		$92K Buy
1,047
+687
+191% +$76.1K ﹤0.01% 3231
2018
Q4 		$51K Sell
360
-60
-14% -$10.1K ﹤0.01% 3549
2018
Q3 		$107K Sell
420
-40
-9% -$11.1K ﹤0.01% 3485
2018
Q2 		$117K Sell
460
-473
-51% -$117K ﹤0.01% 3445
2018
Q1 		$188K Sell
933
-1,954
-68% -$390K ﹤0.01% 2840
2017
Q4 		$416K Sell
2,887
-880
-23% -$141K ﹤0.01% 2408
2017
Q3 		$620K Buy
3,767
+727
+24% +$104K 0.01% 1909
2017
Q2 		$413K Sell
3,040
-2,167
-42% -$321K ﹤0.01% 2106
2017
Q1 		$1M Buy
5,207
+4,180
+407% +$671K 0.01% 1336
2016
Q4 		$145K Sell
1,027
-333
-24% -$45K ﹤0.01% 2617
2016
Q3 		$198K Buy
1,360
+1,153
+557% +$139K ﹤0.01% 2477
2016
Q2 		$21K Sell
207
-1,300
-86% -$169K ﹤0.01% 3773
2016
Q1 		$202K Buy
1,507
+287
+24% +$31.7K ﹤0.01% 2310
2015
Q4 		$242K Sell
1,220
-2,667
-69% -$577K ﹤0.01% 2357
2015
Q3 		$614K Buy
3,887
+3,874
+29,800% +$1.04M 0.01% 1615
2015
Q2 		$5K Sell
13
-134
-91% -$57.9K ﹤0.01% 4492
2015
Q1 		$67K Buy
147
+134
+1,031% +$57.8K ﹤0.01% 3172
2014
Q4 		$7K Sell
13
-107
-89% -$60.8K ﹤0.01% 4353
2014
Q3 		$63K Buy
+120
New +$67.7K ﹤0.01% 3370

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Group One Trading's KPTI Position: Q1 2026 in Review

Group One Trading increased its Karyopharm Therapeutics (KPTI) stake by 87% in Q1 2026, buying an estimated $679K and bringing the position to 191,527 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #2646.

Group One Trading first reported a position in KPTI in Q3 2014 and has held it in 27 quarters since. The position peaked at $1.31M in Q4 2020. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Group One Trading held 191,527 shares of Karyopharm Therapeutics worth $1.07M as of Q1 2026.
  • Group One Trading bought 89,108 Karyopharm Therapeutics shares in Q1 2026, an estimated $679K.
  • Karyopharm Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #2646 holding.
  • Group One Trading first reported a position in Karyopharm Therapeutics in Q3 2014 and has held it in 27 quarters since.
  • Group One Trading's Karyopharm Therapeutics position peaked at $1.31M in Q4 2020.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.